[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subarachnoid-hemorrhage\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subarachnoid-hemorrhage":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,30,0,25,[9,52,89,111,138,164,209,233,258,281,302,327,356,379,404,431,470,491,513,540,563,596,627,657,684],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100377049","improving-outcomes-for-patients-with-life-threatening-neurologic-illness-100377049",false,"NCT04189471","Improving Outcomes for Patients With Life-Threatening Neurologic Illness","Recovery After Cerebral Hemorrhage--Improving Outcomes for Patients With Life-Threatening Neurologic Illness","REACH","Inclusion Criteria:\n\n* clinical diagnosis of potentially life-threatening neurological illness\n* admitted to Neuro ICU within 14 days of initial injury\n\nExclusion Criteria:\n\n* known pre-existing neurological deficits related to a developmental disorder\n* prior severe stroke\n* prior severe dementia\n* prior severe head injury\n* prisoners","ALL","18 Years",{"count":21,"type":22},5000,"ESTIMATED","12 Months","OBSERVATIONAL","Background:\n\nWhile the intensive care of patients with life-threatening brain illnesses has advanced tremendously, a large number of therapies are still without proper scientific support.\n\nThis can be partly explained by the fact that mechanisms of initial brain injury are still not well understood. Why additional neurological injury occurs during a patient's stay in the NeuroCritical Care Unit (NCCU) despite current best, evidence-based clinical practices, is also not well understood. However, over the past decade, better tools have become available to measure and monitor the impact of our clinical care on the rapidly changing physiology and chemistry of the injured brain. Some of these tools are CT, MRI, ultrasound, and catheter-based technology measuring blood flow and metabolism. These tools have enabled earlier detection of injury and complications and newer therapeutic strategies.\n\nPurpose:\n\nExamine disease pathways common to all brain injuries seen in the University of Maryland's 22-bed NCCU. Life-threatening neurological illnesses cared for in the NCCU include massive stroke, bleeding in and around the brain (subarachnoid hemorrhage, intracerebral hemorrhage, subdural hemorrhage, intraventricular hemorrhage), brain tumors, difficult to control seizures, neurologic infections, nerve and muscle diseases (such as myasthenia gravis or Guillain-Barre Syndrome), and spinal cord disorders among others. Many NCCU patients are comatose or paralyzed and may suffer injuries in other parts of the body as well.\n\nThis effort will require the creation of a robust clinical database for the capture of data including patient characteristics (age, sex), clinical characteristics, medical treatments, surgical interventions, physiological data (such as vital signs, cerebral blood flow, intracranial pressure, cerebral oximetry, etc), laboratory data, and standard-of-care diagnostic studies such as electroencephalography (EEG), ultrasound, CT, MRI, and angiograms. Similar databases exist at other major centers for neurocritical care and have been instrumental to the identification of characteristics both predictive of and associated with outcomes of patients long after their stay in the NCCU.\n\nIn addition, the samples collected will be included in the University of Maryland Medicine (UMM) Biorepository which is a shared resource to enable biomedical research by University of Maryland faculty.",[27,28,29,30,31],"Intracerebral Hemorrhage","Subarachnoid Hemorrhage","Intraventricular Hemorrhage","Nontraumatic Haemorrhage","Status Epilepticus",[33,34,35,30,36,37,38],"hemorrhage","intracerebral hemorrhage","SAH","ICH","subarachnoid hemorrhage","status epilepticus","RECRUITING","2026-06-30",{"date":42,"type":43},"2026-07-02","ACTUAL",{"date":45,"type":43},"2014-09-08",{"date":47,"type":22},"2034-01-01",{"name":49,"class":50},"University of Maryland, Baltimore","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":88},"100639121","strategies-for-weaning-from-external-ventricular-drainage-100639121","NCT07630051","Strategies for Weaning From External Ventricular Drainage","SEVDVE2","Inclusion Criteria:\n\n* Adult patient (≥18 years)\n* Admitted to critical care for non-traumatic subarachnoid hemorrhage for less than 3 days\n* First external ventricular drain inserted within the last 3 days for hydrocephalus and\u002For intracranial hypertension\n* Patient consent, or consent from a relative, or inclusion under emergency inclusion procedure\n* Patient affiliated to or beneficiary of a social security scheme\n\nExclusion Criteria:\n\n* Moribund patient or patient with established treatment limitation\u002Fwithdrawal decisions\n* Patient with a pre-existing ventriculoperitoneal or ventriculoatrial shunt\n* Patient with chronic hydrocephalus\n* Pregnant, lactating, or parturient woman\n* Person deprived of liberty by judicial or administrative decision\n* Person under involuntary psychiatric care\n* Person under a legal protection measure\n* Concurrent participation in another study involving external ventricular drainage management",{"count":60,"type":22},170,"INTERVENTIONAL",[63],"NA","External ventricular drainage is frequently used in neurocritical care, particularly in patients admitted for non-traumatic subarachnoid hemorrhage who develop hydrocephalus and\u002For intracranial hypertension. While external ventricular drainage is often initially lifesaving, its prolonged maintenance is associated with complications, especially infections and prolonged hospital length of stay. There is currently no consensus on the optimal weaning strategy. Two approaches are used in routine practice: direct clamping (the external ventricular drain is closed as soon as weanability criteria are met) and gradual weaning (the external ventricular drain level is progressively raised before final clamping). No randomized controlled trial has yet demonstrated the superiority of one strategy over the other in patients with non-traumatic subarachnoid hemorrhage.\n\nThe investigators hypothesize that a direct clamping strategy, combined with daily screening of standardized weanability criteria, will reduce the duration of external ventricular drain maintenance compared with the conventional gradual weaning strategy. SEVDVE-2 is a multicenter, randomized, controlled, parallel-group, single-blind superiority trial that will compare these two weaning strategies in 170 adult patients admitted to critical care for non-traumatic subarachnoid hemorrhage with a first external ventricular drain inserted within the previous 3 days. Patients will be randomized 1:1, stratified on the presence of an intraventricular hematoma. The primary outcome is the number of external ventricular drain-free days alive at Day 28.",[28,66,67,68],"Hydrocephalus","Intracranial Hypertension","External Ventricular Drainage",[70,28,71,72,73,74,75,76],"External Ventricular Drain","Weaning; Hydrocephalus","Intracranial Pressure","Neurocritical Care","Direct Clamping","Gradual Weaning","Randomized Controlled Trial","NOT_YET_RECRUITING","2026-06-01",{"date":80,"type":43},"2026-06-05",{"date":82,"type":22},"2026-07-01",{"date":84,"type":22},"2031-10-01",{"name":86,"class":87},"University Hospital, Angers","OTHER_GOV",5,{"id":90,"slug":91,"hasResults":12,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":61,"phases":97,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":51},"100301209","impact-of-nmes-and-hpro-on-recovery-after-sah--pilot-study-100301209","NCT03201094","Impact of NMES and HPRO on Recovery After SAH- Pilot Study","Impact of Neuromuscular Stimulation and High Protein Nutritional Supplementation on Long-term Recovery After Aneurysmal Subarachnoid Hemorrhage.","Inclusion criteria:\n\n1. . Being diagnosed with aneurysmal SAH\n2. . Aneurysmal repair within 48 hours of ictus.\n3. . Age between 25 and 80 years old. (\\>=25 years old and \\\u003C=80 years old)\n4. . Expected stay in the NCCU \\> 72 hours.\n5. . Admission Hunt Hess Grade \\>=2.\n6. modified Fisher score \\>1.\n\nExclusion criteria:\n\n1. . Subjects diagnosed with SAH from trauma, rupture of an arteriovenous malformation, neoplasm, vasculitis, or other secondary causes;\n2. . Unlikely to survive one week post hemorrhage either due to impending brain death or likely request for withdrawal of care;\n3. . Unlikely to remain in the ICU for more than 7 days;\n4. . Body mass index \\\u003C 15 or \\>40 kg\u002Fm2;\n5. . Allergy to whey protein;\n6. . Evidence of lower extremity paresis or spasticity within 48 hours of injury\n7. . Pre-morbid modified Rankin Score \\>1.\n8. . Known pregnancy\n9. . Presence of active malignancy\n10. . Diagnosis of an inflammatory disorder\n11. . Presence of a neuromuscular disorder\n12. . Diagnosis of chronic renal insufficiency or acute kidney injury (GFR \\\u003C 30 mL\u002Fmin\u002F1.73m2)\n13. . Hepatic insufficiency defined as AST\u002FALT levels \\>2.5 above normal upper limits.\n14. . On-going seizure activity as assessed clinically or by electrographic detection on continuous electroencephalogram (cEEG) at time of enrollment\n15. . Prisoner.",{"count":5,"type":22},[63],"The study purpose is to investigate the hypothesis that in adults with SAH, early neuromuscular electrical stimulation (NMES) and high protein supplementation (HPRO) will improve muscle mass, metabolic and inflammatory biomarker profiles, compared to SAH controls receiving standard of care interventions for nutrition and mobilization. The investigators will accomplish this by studying the effects of a high protein (HPRO) nutritional treatment as well as NMES intervention have upon muscle wasting and motor strength acutely after SAH. This will be addressed in a prospective trial of SAH patients receiving HRPO with NMES as compared to age and severity-matched SAH patients undergoing standard of care interventions for nutrition and mobilization. Additionally, the study will investigate the impact HPRO and NMES interventions have upon inflammatory cytokines and markers of energy balance. Results of this study will establish evidence for precision nutrition plus early exercise to mitigate the catabolic and inflammatory state produced by SAH to improve muscle, metabolic, and health recovery outcomes.",[28,100,101,102],"Muscle Atrophy","Inflammation","Nutritional and Metabolic Disease","2026-05-15",{"date":105,"type":43},"2026-05-19",{"date":107,"type":43},"2017-12-01",{"date":109,"type":22},"2026-10-30",{"name":49,"class":50},{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":12,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":61,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100365848","crystalloid-fluid-choice-and-neurological-outcome-in-patients-after-subarachnoid-haemorrhage-100365848","NCT04043598","Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage","Crystalloid Fluid Choice and Neurological Outcome in Patients After Subarachnoid Haemorrhage - a Multi-center Randomized Double-blind Clinical Trial","CRYSTALLBrain","Inclusion Criteria:\n\nAll adult patients suffering from non-traumatic subarachnoid haemorrhage.\n\nExclusion Criteria:\n\n* Patients with major intra-cranial trauma\n* Diagnosis of an AV-malformation as the source of subarachnoid hemorrhage on the primary CT\u002FMRI or angiography\n* More than 24 hours after diagnosis of subarachnoid haemorrhage as diagnosed by cerebral imaging (CT scan or MRI)\n* Patients with clear limitation to therapy at hospital admission (eg ICU admission for evaluation of organ donation)\n* Declining of informed consent","16 Years",{"count":121,"type":22},320,[63],"Patients with subarachnoid hemorrhage are prone to suffer from dysnatriemia. Evidence shows that hyponatriemia is associated with increased incidence of vasospasm, brain swelling and mortality in these patients. Patients with subarachnoid hemorrhage often require large amounts of iv fluids in order to maintain euvolemia and support cardiocirculatory function. Prior evidence shows that the type of infusion fluid significantly influences blood sodium content. Hence, this study evaluated whether the sodium content of the infusion solution impacts mortality and morbidity in patients with subarachnoid hemorrhage.",[28,125,126,127],"Critical Illness","Infusion Fluid","Sodium Disorder","2026-04-28",{"date":130,"type":43},"2026-04-29",{"date":132,"type":43},"2022-05-24",{"date":134,"type":22},"2027-12",{"name":136,"class":50},"Insel Gruppe AG, University Hospital Bern",3,{"id":139,"slug":140,"hasResults":12,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":61,"phases":147,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":51},"100611903","phase-4-lumbar-drain-with-intrathecal-nicardipine-in-aneurysmal-subarachnoid-hemorrhage-100611903","NCT07246629","Lumbar Drain With Intrathecal Nicardipine in Aneurysmal Subarachnoid Hemorrhage","Prophylactic Use of Intrathecal Calcium Channel Antagonist Through Lumbar Drain in Patients With Subarachnoid Hemorrhage Due to Aneurysmal Rupture","Inclusion Criteria:\n\n* Age ≥18 years\n* Aneurysmal subarachnoid hemorrhage with Hunt and Hess score 3 or less\n* Patient or legal authorized representative available to sign the informed consent form\n* Pre-morbid modified Rankin scale of 0 or 1.\n* Patients who have lumbar drain placed or planned for cerebrospinal fluid diversion per standard of care\n* Patients who are able to be randomized within 72 hours from arrival with aneurysmal subarachnoid hemorrhage or within 24 hours from lumbar drain placement\n\nExclusion Criteria:\n\n* Pregnant females\n* Subarachnoid hemorrhage (SAH) with hunt and hess scale of \\>3\n* SAH due to etiology other than aneurysmal rupture\n* Any contraindications in patients receiving calcium channel antagonists like hypersensitivity to dihydropyridines\n* Active central nerve infection (CNS) infection or high suspicion of CNS infection\n* Hemodynamic instability preventing the use of Nicardipine",{"count":146,"type":22},214,[148],"PHASE4","The purpose of this study is to determine the effectiveness of prophylactic administration of intra-thecal nicardipine though lumbar cerebrospinal fluid drain in prevention of symptomatic vasospasm in patients with subarachnoid hemorrhage due to rupture of cerebral aneurysms.",[28],[152,153,154],"cerebral aneurysm","intrathecal nicardipine","vasospasm","2026-04-23",{"date":157,"type":43},"2026-04-24",{"date":159,"type":22},"2026-06",{"date":161,"type":22},"2027-01",{"name":163,"class":50},"Wake Forest University Health Sciences",{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":174,"conditions":175,"keywords":197,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100571728","neurosurgical-outcome-network-100571728","NCT06724029","Neurosurgical Outcome Network","Neurosurgical Outcome Network Per la Predizione Dell'Outcome in Neurochirurgia","NEON","Inclusion Criteria:\n\n* Neuro-oncological pathology: supratentorial and subtentorial tumors, intra and extra axial tumors excluding the skull base (anterior, middle and posterior fossa; sellar and parasellar region)\n* Basicranial pathology: tumors originating from the anterior cranial fossa, middle cranial fossa and posterior cranial fossa, sellar region with or without supratentorial\u002Fparasellar development.\n* Vascular pathology: aneurysms, AVMs, cavernomas, other pathologies (Moyamoya disease, dural fistulas, nontraumatic hematomas)\n* Traumatic pathology: diffuse damage (nonvisible diffuse damage, diffuse damage, diffuse damage with edema, diffuse damage with shift) and focal damage (acute\u002Fsubacute\u002Fchronic subdural hematoma, extradural hematoma, subarachnoid hemorrhage, intraparenchymal hematoma, fractures); hydrocephalus. The inclusion criterion for chronic subdural hematoma is recent bleeding for TBI with CT finding of chronic subdural hematoma candidate for evacuation surgery.\n* Spinal pathology: degenerative cervical (anterior\u002Fposterior), myelopathic, and trauma pathology; instrumented, uninstrumented thoracolumbar pathology (disc pathology, canal pathology), and trauma pathology; oncologic spinal pathology.\n* Functional pathology: Parkinson's disease, spasticity, trigeminal neuralgia, craniofacial pain\u002Falgia, neuropathic pain, tremor, dystonias, obsessive compulsive disorder, drug-resistant epilepsies, depression. Normotensive hydrocephalus.\n* Peripheral nervous system pathology: peripheral nerve compression syndromes, peripheral nerve and plexus tumors, brachial plexus and peripheral nerve trauma (contusion and section)\n* Malformative pathology: Chiari malformation type 1 and craniostenoses including both those framed in malformative syndromes and those not framed in malformative syndromes (monosutural craniostenoses: trigonocephaly, plagiocephaly, scaphocephaly; multisutural craniostenoses). Malformative hydrocephalus.\n* For cognitive and psychological assessment: age 18 years or older; adequate understanding of Italian language; diagnosis of glioma, meningioma, vascular pathology, spinal pathology\n\nExclusion Criteria:\n\n* For cognitive and psychological assessment: patients with psychiatric diseases in history and\u002For taking psychotropic drugs; presence of overt cognitive decline (not due to the injury) in history; patients younger than 18 years old.",{"count":173,"type":22},4500,"The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to assess outcomes and their predictors using measures agreed upon by the participating centers. Standardizing the evaluation of outcomes and predictors improves the quality of research, allows for data comparison, and facilitates a \"common language\" in routine clinical practice. Most importantly, it influences therapeutic decisions in various neurosurgical conditions. Clinically, the identified predictors can also be used during preoperative assessments to provide more precise guidance to patients undergoing surgery.",[176,177,178,179,180,181,182,183,28,66,184,185,186,187,188,189,190,191,192,193,194,195,196],"Aneurysms","Arteriovenous Malformations","Cavernomas","Skull Base Tumors","Moyamoya Disease","Dural Fistulas","Subdural Hematoma","Extradural Hematoma","Parkinson&Amp;#39;s Disease","Spasticity","Trigeminal Neuralgia","Craniofacial Pain","Neuropathic Pain","Tremor","Dystonias","Obsessive-compulsive Disorder","Drug-resistant Epilepsy","Depression","Normal Pressure Hydrocephalus","Tumors of Peripheral Nerves","Chiari Malformation Type 1",[198],"Neurosurgery Outcome Artificial Intelligence predictors","2026-03-25",{"date":201,"type":43},"2026-03-30",{"date":203,"type":43},"2022-12-05",{"date":205,"type":22},"2027-06",{"name":207,"class":50},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",27,{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":216,"targetDuration":218,"studyType":24,"phases":4,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":226,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":51},"100530865","ventilatory-parameters-in-acute-neurological-injury-100530865","NCT06192342","Ventilatory Parameters in Acute Neurological Injury","Baseline Ventilatory Parameters in Patients With Acute Neurological Injury","Inclusion Criteria:\n\nAcute neurological injury in patients ≥ 16 years of age with requiring mechanical ventilation for neurological causes and without baseline lung injury, defined as: normal chest x-ray and adequate oxygenation; PaO2\u002FFiO2 ≥ 300.Neumovent TS and Neumovent Advance respirators will be used.\n\n\\-\n\nExclusion Criteria:\n\nPneumothorax, or a pleural drainage tube. Hemodynamic instability (mean blood pressure ≤ 65 mmHg) or high doses of inotropes (Norepinephrine \\> 0.5 gammas\u002Fkilo\u002Fminute or equivalent).\n\nPaO2\u002FFiO2 \\\u003C 80 mmHg. Chronic obstructive pulmonary disease (COPD). Pregnant",{"count":217,"type":22},19,"2 Years","The goal of this observational study is to test the association between baseline ventilatory parameters (in particular mechanical power (MP), mechanical power normalized to predicted body weight (MP\u002FPBW) and driving pressure (DP) with the baseline neurological status (assessed through the Glasgow coma score) in adults patients under mechanical ventilation with acute neurological injury secondary to stroke, brain trauma or subarachnoid hemorrhage.\n\nThe main question\\[s\\]it aims to answer are:\n\n1. In patients with acute neurological injury under mechanical ventilation, is there a correlation between the acute neurological injury, assessed using the Glasgow scale on admission, and baseline ventilatory parameters?\n2. In patients with acute neurological injury under mechanical ventilation, are the baseline ventilatory parameters altered at baseline?",[221,222,223,28],"Neurologic Decompensation, Acute","Traumatic Brain Injury","Stroke",[225],"acute neurological injury, mechanical ventilation",{"date":201,"type":43},{"date":228,"type":43},"2024-05-01",{"date":230,"type":22},"2027-05-30",{"name":232,"class":50},"Ramos Mejía Hospital",{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":61,"phases":242,"briefSummary":244,"conditions":245,"keywords":247,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":256,"locationsCount":51},"100439396","phase-1-prophylactic-antibiotics-useful-with-antibiotic-impregnated-external-ventricular-drains-evds-100439396","NCT05001750","Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?","Are Long Term Prophylactic Antibiotics Useful With Antibiotic Impregnated External Ventricular Drains (EVDs)?","Inclusion Criteria:\n\n* patients over the age of 18 years\n* patients diagnosed with a subarachnoid hemorrhage, intracerebral hemorrhage, or acute ischemic stroke who require an EVD for management of their underlying condition. In certain cases (a small minority), an EVD must be replaced due to failure (i.e., blood clot interrupting flow). In such cases, patients will be re-dosed with antibiotics prior to catheter exchange in typical fashion and continue in their previously randomized treatment group\n\nExclusion Criteria:\n\n* patients who were on antibiotics within the week prior to admission\n* patients with leukopenia (\\\u003C5000) at baseline\n* patients with signs of meningitis, ventriculitis or any other infection at presentation\n* patients who are pregnant or prisoners\n* patients aged \\\u003C 18 years old",{"count":241,"type":22},84,[243],"PHASE1","The principal objective of this study is to compare the incidence of ventriculostomy related infections (VRIs) in patients who receive twenty-four hours of antibiotics, beginning no more than sixty minutes prior to EVD placement, to the incidence of VRIs in patients who also receive a pre-procedural dose of antibiotics with continued dosing of antibiotics for the duration of the external ventricular drain (EVD). At this time, the duration of prophylactic antibiotic use with antibiotic impregnated EVDs is unknown.",[28,27,246,66],"Ventriculitis, Cerebral",[248,27,249,66],"Subarachnoid hemorrhage","Ventriculitis","2026-01-29",{"date":252,"type":43},"2026-02-02",{"date":254,"type":43},"2021-06-14",{"date":159,"type":22},{"name":257,"class":50},"Montefiore Medical Center",{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":61,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":51},"100405303","auricular-vns-following-subarachnoid-hemorrhage-100405303","NCT04557618","Auricular VNS Following Subarachnoid Hemorrhage","Transcutaneous Auricular Vagus Nerve Stimulation Following Spontaneous Subarachnoid Hemorrhage","Inclusion Criteria:\n\n* Spontaneous subarachnoid hemorrhage\n\nExclusion Criteria:\n\n* Trauma-induced subarachnoid hemorrhage\n* Ongoing chemotherapy\n* Taking immunosuppressive medications for other medical illnesses\n* Presence of a pacemaker\n* Prolonged bradycardia at time of admission",{"count":266,"type":22},50,[63],"This study will evaluate whether non-invasive auricular vagal nerve stimulation lowers inflammatory markers, and improves outcomes following spontaneous subarachnoid hemorrhage.",[28],[271],"Vagal nerve stimulation","2025-12-18",{"date":274,"type":43},"2025-12-26",{"date":276,"type":43},"2021-01-05",{"date":278,"type":22},"2028-12",{"name":280,"class":50},"Anna Huguenard",{"id":282,"slug":283,"hasResults":12,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":289,"conditions":290,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":51},"100577396","effect-of-the-stellate-ganglion-block-on-the-retinal-microcirculation-100577396","NCT06797752","Effect of the Stellate Ganglion Block on the Retinal Microcirculation","Effect of the Stellate Ganglion Block on the Retinal Microcirculation: A Pilot Study","Inclusion Criteria:\n\n* Age 18 years or older\n* Patients receiving the stellate ganglion nerve block for an approved indication, e.g. complex regional pain syndrome\n\nExclusion Criteria:\n\n* Pregnancy\n* Non-English speaking\n* Temporary or permanent physical limitation that renders the patient unable to sit up and look inside OCTA device",{"count":266,"type":22},"Surges in the sympathetic nervous system occur at the ictus of a variety of neurological critical illnesses including intracranial hemorrhage and ischemic stroke. It is hypothesized that these exaggerated increases in sympathetic nervous activity produce maladaptations that promote secondary brain injury. One of these possible mechanisms include diffuse vasospasm that cause cerebral ischemia. Hence, methods to abrogate the sympathetic nervous system in this context are under active investigation. One possible method is the regional anesthesia technique of the stellate ganglion nerve block, which is ordinarily used for complex regional pain syndrome, but has been shown to reduce cerebral sympathetic activity and reduces vasospasm in patients with subarachnoid hemorrhage. However, its effect on the microcirculation is not clear. Hence, we propose to study patients receiving the stellate ganglion nerve block as part of their standard medical care and to image their retinal microcirculation before and after the procedure using Optical Coherence Tomography Angiography (OCTA).",[291,292,28,27],"OCTA","Severe Brain Injury","2025-11-15",{"date":295,"type":43},"2025-11-19",{"date":297,"type":43},"2024-10-07",{"date":299,"type":22},"2026-10-07",{"name":301,"class":50},"University of Texas Southwestern Medical Center",{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":311,"conditions":312,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":322,"leadSponsor":324,"locationsCount":326},"100432830","determinants-of-incident-stroke-cognitive-outcomes-and-vascular-effects-on-recovery-100432830","NCT04916210","Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY","DISCOVERY","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Admitted to the enrolling clinical performance site (CPS) hospital with a diagnosis of acute ischemic stroke (AIS), intracerebral hemorrhage (ICH), or aneurysmal subarachnoid hemorrhage (aSAH)\n3. Radiographic confirmatory evidence of: (1) AIS (based on a focal area of restricted diffusion on MRI), (2) non-traumatic primary ICH (based on evidence of acute parenchymal hemorrhage on CT or brain MRI) or (3) non-traumatic acute aSAH (based on evidence of subarachnoid hemorrhage on CT or MRI and evidence of aneurysm on CT angiography, MR angiography, or conventional catheter-based angiography)\n4. Able to complete baseline visit in person or by phone within 6 weeks of stroke onset\n5. Able to provide informed consent by self or proxy\n6. Fluent in English or Spanish prior to stroke onset\n\nExclusion Criteria:\n\n1. Documented history of pre-stroke dementia or fails dementia pre-screen\n2. Concurrently enrolled into a study that is not approved under the DISCOVERY Co-Enrollment Policy\n3. Unable to complete study protocol (advanced directives such as comfort measures only, or inability to complete the study due to severe medical\u002Fbehavioral co-morbidities), as determined by physician investigator during screening process\n\n   Additional exclusion criteria for Tier 2 participants:\n4. Contraindication to MRI: presence of electrically, magnetically, or mechanically activated implants (such as cardiac pacemakers, cochlear implants, implanted pumps); or metallic clips in the brain\n\n   Additional exclusion criteria for Tier 3 participants:\n5. Age \\\u003C50 years\n6. Biologically female individuals who are pregnant or seeking to become pregnant\n7. Known to have one of the following genetic conditions which can increase the risk of developing cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, Down's syndrome.",{"count":310,"type":22},8000,"The overall goal of the DISCOVERY study is to better understand what factors contribute to changes in cognitive (i.e., thinking and memory) abilities in patients who experienced a stroke. The purpose of the study is to help doctors identify patients at risk for dementia (decline in memory, thinking and other mental abilities that significantly affects daily functioning) after their stroke so that future treatments may be developed to improve outcomes in stroke patients. For this study, a \"stroke\" is defined as either (1) an acute ischemic stroke (AIS, or blood clot in the brain), (2) an intracerebral hemorrhage (ICH, or bleeding in the brain), (3) or an aneurysmal subarachnoid hemorrhage (aSAH, or bleeding around the brain caused by an abnormal bulge in a blood vessel that bursts).\n\nThe investigators hypothesize that:\n\n1. The size, type and location of the stroke play an important role in recovery of thinking and memory abilities after stroke, and pre-existing indicators of brain health further determine the extent of this recovery.\n2. Specific stroke events occurring in individuals with underlying genetic or biological risk factors can cause further declines in brain heath, leading to changes in thinking and memory abilities after stroke.\n3. Studying thinking and memory alongside brain imaging and blood samples in patients who have had a stroke allows for earlier identification of declining brain health and development of individualized treatment plans to improve patient outcomes in the future.",[313,27,28,314,315,316],"Ischemic Stroke","Dementia, Vascular","Mild Cognitive Impairment","Vascular Cognitive Impairment","2025-10-31",{"date":319,"type":43},"2025-11-03",{"date":321,"type":43},"2021-03-05",{"date":323,"type":22},"2026-08-31",{"name":325,"class":50},"Massachusetts General Hospital",31,{"id":328,"slug":329,"hasResults":12,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":334,"targetDuration":336,"studyType":24,"phases":4,"briefSummary":337,"conditions":338,"keywords":345,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":347,"lastUpdatePostDateStruct":348,"startDateStruct":350,"completionDateStruct":352,"leadSponsor":354,"locationsCount":51},"100310212","stroke-recovery-initiative---registry-for-stroke-research-studies-100310212","NCT03318432","Stroke Recovery Initiative - Registry for Stroke Research Studies","Stroke Recovery Initiative - Stroke Registry","* 18 years of age or older\n* Have suffered a stroke\n* Have ongoing symptoms as a result of the stroke",{"count":335,"type":22},60000,"5 Years","The Stroke Recovery Initiative is a nation-wide participant recruitment registry that connects people who have had a stroke with researchers who are working to develop new approaches to improve recovery after stroke.",[223,339,313,340,28,341,342,343,344],"Acute Stroke","Hemorrhagic Stroke","Cerebral Ischemia","Cerebral Infarction","Cerebral Stroke","Cerebral Vascular Accident",[223,339,313,340,341,342,343,344,346],"Stroke Recovery","2025-09-26",{"date":349,"type":43},"2025-10-02",{"date":351,"type":43},"2013-02-09",{"date":353,"type":22},"2028-09",{"name":355,"class":50},"University of California, San Francisco",{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":370,"lastUpdatePostDateStruct":371,"startDateStruct":373,"completionDateStruct":375,"leadSponsor":377,"locationsCount":51},"100397798","intracranial-pressure-time-dose-impeto-100397798","NCT04459806","Intracranial PrEssure Time dOse (ImPETO)","Evaluation of Intracranial Pressure Time Dose by the New Integra CereLink ICP Monitor","ImPETO","Inclusion Criteria:\n\n* Aged within 18 and 80 years;\n* Diagnosed of an acute brain injury (ABI) for hemorrhagic stroke (including intracerebral hematoma or subarachnoid hemorrhage) or traumatic brain injury;\n* ICP monitoring started for clinical indication and accordingly to local policies\n* ICP device connected to the Integra CereLink ICP monitor.\n\nExclusion Criteria:\n\n* ICP monitoring not inserted\n* No availability of the Integra CereLink ICP monitor.","80 Years",{"count":366,"type":22},250,"The new Integra CereLink ICP monitor integrate the possibility of recording and displaying continuously the AUC (Pressure Time Dose, PTD) and other ICP derived variables and provide the possibility of evaluating the utility of this information at the bedside. It offers the opportunity to test in a standardized way the clinical value of the PTD computation in this setting.\n\nTherefore, this study aims to test clinically if PTD recorded continuously is associated to patients' outcome and to identify a threshold of PTD associated with the transition from good to negative outcomes.",[67,222,28,369],"Intracranial Hemorrhages","2025-09-08",{"date":372,"type":43},"2025-09-15",{"date":374,"type":43},"2023-11-13",{"date":376,"type":22},"2026-12-31",{"name":378,"class":50},"University of Milano Bicocca",{"id":380,"slug":381,"hasResults":12,"nctId":382,"briefTitle":383,"officialTitle":384,"acronym":4,"eligibilityCriteria":385,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":364,"enrollmentInfo":386,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":395,"lastUpdatePostDateStruct":396,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":4},"100601819","development-and-validation-of-a-prognostic-model-for-neurocritical-patients-using-multimodal-brain-monitoring-100601819","NCT07115459","Development and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring","Protocol for Developing and Validating a Multimodal Brain Monitoring-Based Prognostic Model for Neurocritical Patients: A Prospective, Observational, Multicenter Cohort Study","Inclusion Criteria:\n\n1. Aged 18-80 years, no gender restrictions.\n2. Diagnosed with acute brain injury (ABI), including one of the following: large cerebral infarction, supratentorial large-volume intracerebral hemorrhage, subarachnoid hemorrhage, or severe traumatic brain injury, with imaging evidence (CT or MRI) supporting the diagnosis.\n3. On ICU admission, Glasgow Coma Scale (GCS) eye response = 1 (no eye opening) and motor score ≤ 5 (does not follow commands); or within 48 hours, neurological deterioration with no eye opening and motor score reduced to ≤ 5 (total GCS score ≤ 8).\n4. Able to undergo continuous multimodal monitoring, with an expected ICU stay of ≥72 hours.\n5. Informed consent signed by the family or legal representative.\n\nExclusion Criteria:\n\n1. Confirmed brain death on admission or imaging showing irreversible brain herniation.\n2. Severe trauma unrelated to brain injury (e.g., multiple fractures, spinal cord injuries, or visceral rupture) that may interfere with brain function monitoring or outcome assessment.\n3. Pre-existing severe neurological disorders such as epilepsy, severe encephalopathy, or chronic intracranial conditions (e.g., brain tumors or hydrocephalus).\n4. Inability to perform multimodal monitoring due to technical issues (e.g., equipment failure or sensor installation problems).\n5. Predicted survival time \\\u003C24 hours after admission, or family members choose to withdraw treatment.\n6. Refusal to participate in the study by the patient or their legal representative.",{"count":387,"type":22},167,"This study aims to develop and validate a prognostic model for neurocritical patients using multimodal brain monitoring data. By combining data from various monitoring techniques such as EEG, TCD, and NIRS, this model will help predict 90-day outcomes (awake, comatose, or deceased) and support personalized treatment decisions. The study is observational and involves no experimental interventions.",[390,73,342,369,28,391],"Acute Brain Injury Coma","Severe Traumatic Brain Injury",[393,394],"Multimodal Brain Monitoring","Prognostic Model","2025-08-03",{"date":397,"type":43},"2025-08-11",{"date":399,"type":22},"2025-08-15",{"date":401,"type":22},"2026-11-15",{"name":403,"class":50},"Xiangya Hospital of Central South University",{"id":405,"slug":406,"hasResults":12,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":410,"eligibilityCriteria":411,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":364,"enrollmentInfo":412,"targetDuration":4,"studyType":61,"phases":414,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":51},"100570750","remote-ischemic-conditioning-for-efficacy-in-patients-with-aneurysmal-subarachnoid-hemorrhage-100570750","NCT06711302","Remote Ischemic Conditioning for Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage","Remote Ischemic Conditioning for Efficacy in Patients With Aneurysmal Subarachnoid Hemorrhage: a Multi-center, Randomized, Double-blind, Sham-controlled, Parallel-group Trial","REPAIR","Inclusion Criteria:\n\n1. Patients with aneurysmal subarachnoid hemorrhage confirmed by imaging examination (diagnosed by computed tomography and confirmation of an intracranial aneurysm by CT angiography or digital subtraction angiography);\n2. The Hunt-Hess grade is 2-3 at admission;\n3. Onset of aneurysmal subarachnoid hemorrhage ≤72 hours;\n4. The responsible aneurysm has been treated by endovascular interventional therapy;\n5. 18≤ age ≤80 years old;\n6. Informed consent must be obtained from participants or legally authorized representatives.\n\nExclusion Criteria:\n\n1. Patients with other intracerebral hemorrhage or other types of subarachnoid hemorrhage;\n2. Previous neurological deficits (mRS Score ≥1) or psychiatric disorders that can confound neurological or functional assessments;\n3. With severe comorbidities and a life expectancy of less than 90 days;\n4. Refractory hypertension (Systolic blood pressure\\> 180 mmHg or diastolic blood pressure \\>110 mmHg);\n5. Contraindications of RIC: severe soft tissue injury of the lower limbs, etc;\n6. Concurrent participation in another protocol investigating a different experimental therapy;\n7. Any condition that the investigator believes may increase the patient's risk.",{"count":413,"type":22},500,[63],"Several recent large-scale clinical trials aimed at improving subarachnoid hemorrhage(SAH) outcomes have concluded with negative results, failing to enhance the prognosis for these patients. Consequently, there is an urgent demand for novel treatment strategies and approaches to address the challenges posed by SAH.\n\nRemote ischemic conditioning(RIC) has gained considerable attention in the treatment of stroke, particularly ischemic stroke, with numerous studies demonstrating its potential to enhance neurological outcomes compared to conventional treatments alone.RIC for the treatment of SAH is an investigative strategy in its initial stages. The neuroprotective effects of RIC, particularly its potential to preserve cranial nerve function and ameliorate neurological deficits, confer significant value in the treatment of SAH patients.\n\nThe precise manner in which SAH patients may benefit from RIC treatment, and the mechanisms by which it improves neurological function, remain to be fully understood. Consequently, randomized controlled trials are necessary to validate the efficacy of RIC in this patient population and to delineate the optimal therapeutic protocols for its application.\n\nBased on the above discussion, this study aims to explore the efficacy and safety of RIC in the treatment of SAH.",[28,417,418,223,419,420,421],"Cerebrovascular Disorders","Brain Diseases","Cardiovascular Diseases","Vascular Diseases","Nervous System Diseases","2025-07-07",{"date":424,"type":43},"2025-07-10",{"date":426,"type":22},"2025-07-01",{"date":428,"type":22},"2026-04-01",{"name":430,"class":50},"Beijing Tiantan Hospital",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":437,"eligibilityCriteria":438,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":441,"conditions":442,"keywords":446,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":461,"lastUpdatePostDateStruct":462,"startDateStruct":464,"completionDateStruct":466,"leadSponsor":468,"locationsCount":51},"100507900","brain-perfusion-evaluation-by-contrast-enhanced-ultrasound-100507900","NCT05893407","Brain PERfusion Evaluation by Contrast-Enhanced UltraSound","Quantification of Cerebral Perfusion at the Patient's Bedside When Performing Contrast-enhanced Ultrasound in Neurointensive Care Patients","PerCEUS","Inclusion Criteria:\n\n* Age ≥18\n* Intensive care unit admission for acute brain injury\n* Proven acute brain injury by CT and\u002For MRI\n* Requiring a contrast ultrasound imaging\n* Informed consent of patient or relative\n\nExclusion Criteria:\n\n* Pregnancy\n* Not sufficient temporal window\n* Contraindications to Sonovue ® : acute coronary syndromes, severe ischemic heart disease (requiring revascularization), pulmonary arterial hypertension \\> 90 mmHg, right-left shunt, ARDS, dobutamine's use, known allergy or adverse reaction to Sonovue®\n* Patient on State Medical Assistance",{"count":440,"type":22},60,"The objective of the study is to assess brain tissue perfusion by contrast-enhanced ultrasound perfusion imaging (PerCEUS) in acute brain injuries. More precisely, it aims :\n\n* to evaluate the heterogeneity of brain perfusion and thus diagnose brain tissue hypoperfusion with contrast-enhanced ultrasound.\n* to correlate contrast-enhanced ultrasound with perfusion measurements by usual multimodal monitoring.",[443,28,313,444,445],"Cerebral Hemorrhage","Cerebrovascular Circulation","Perfusion",[447,448,449,450,451,452,453,454,455,456,457,458,459,460],"Brain perfusion","Cerebral blood flow","Diagnostic imaging","Ultrasonography Doppler","Doppler ultrasound","Transcranial Doppler","Contrast enhanced ultrasound","Contrast-enhanced ultrasonography","Contrast ultrasound","Ultrasound perfusion imaging","Ultrasound contrast agent","Intra-cranial pressure","Intracerebral hematoma","Neurocritical care","2025-06-16",{"date":463,"type":43},"2025-06-19",{"date":465,"type":43},"2023-07-21",{"date":467,"type":22},"2025-07",{"name":469,"class":50},"Assistance Publique - Hôpitaux de Paris",{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":477,"sex":18,"minAge":19,"maxAge":364,"enrollmentInfo":478,"targetDuration":4,"studyType":61,"phases":480,"briefSummary":481,"conditions":482,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":51},"100524014","phase-1-hyperpolarized-13c-pyruvate-metabolic-mri-with-traumatic-brain-injury-100524014","NCT06103201","Hyperpolarized 13C-pyruvate Metabolic MRI With Traumatic Brain Injury","Utility of Hyperpolarized 13C-Pyruvate Metabolic Magnetic Resonance Imaging in the Diagnosis of Early Cerebral Metabolic Crisis After Traumatic Brain Injury","Inclusion Criteria:\n\n* History of acute head injury with or suspected non-penetrating acute TBI\n* Suitable to undergo contrast-enhanced MRI\n* Negative serum pregnancy test\n\nExclusion Criteria:\n\n* Inability to undergo MRI scan\n* Inability to receive IV MRI contrast agents secondary to severe reaction or renal insufficiency\n* Positive pregnancy test",true,{"count":479,"type":22},15,[243],"The purpose of this study is to examine the safety and feasibility of using hyperpolarized metabolic MRI to study early brain metabolism changes in subjects presenting with head injury and suspected non-penetrating traumatic brain injury (TBI). This study will also compare HP pyruvate MRI-derived metrics in TBI patients with healthy subjects as well as Subarachnoid hemorrhage (SAH) patients to better understand if metabolic Magnetic resonance imaging scan (MRI) can improve our ability to diagnose a TBI.\n\nThe FDA is allowing the use of hyperpolarized \\[1-13C\\] pyruvate (HP 13C-pyruvate) in this study.\n\nUp to 15 patients (5 with TBI, 5 with SAH, and 5 healthy volunteers) may take part in this study at the University of Maryland, Baltimore (UMB).",[222,28],"2025-05-06",{"date":485,"type":43},"2025-05-11",{"date":487,"type":43},"2023-10-26",{"date":489,"type":22},"2027-11-26",{"name":49,"class":50},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":499,"targetDuration":4,"studyType":61,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":51},"100489191","affect-study-for-patients-with-intraventricular-hemorrhage-subarachnoid-hemorrhage-subdural-hematoma-and-ventriculitis-100489191","NCT05649904","AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis","Use of Active Fluid Exchange to Therapeutically Treat Intracranial Bleeding and Infection","AFFECT","Inclusion Criteria:\n\n1. Age ≥18 years of age\n2. Need of drainage for one of the following underlying conditions: Intraventricular hemorrhage, intracranial hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis\n3. Indication for active treatment evaluated by treating physician for underlying conditions; Intraventricular hemorrhage, subarachnoid hemorrhage, chronic subdural hematoma and ventriculitis\n4. Signed informed consent obtained by subject or Legally Authorized Representative\n\nExclusion Criteria:\n\n1. Subject has fixed and dilated pupils\n2. Pregnant women\n3. Presence of Moyamoya\n4. History or presence of clotting disorder.\n5. Platelet count less than 100,000, INR greater than 1.4",{"count":500,"type":22},240,[63],"The goal of this clinical trial is to evaluate efficacy and safety of evacuation of cerebrospinal fluid, blood, and harmful bacteria from the intraventricular, subdural and subarachnoid spaces by Active Controlled Irrigation and Drainage (IRRAflow) compared to Passive External Ventricular Drainage (EVD).\n\nSubjects with intraventricular hemorrhage, subarachnoid hemorrhage, subdural bleeding, and ventriculitis will be randomized to receive the IRRAflow device or EVD device and followed for one month post-procedure to compare outcomes between the subject groups.",[29,28,182,249],"2025-03-26",{"date":506,"type":43},"2025-04-01",{"date":508,"type":43},"2023-02-07",{"date":510,"type":22},"2026-01",{"name":512,"class":50},"Ohio State University",{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":61,"phases":522,"briefSummary":523,"conditions":524,"keywords":527,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":531,"lastUpdatePostDateStruct":532,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":51},"100518656","blood-pressure-treatment-in-icu-patients-with-subarachniodal-haemorrhage-100518656","NCT06033378","Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage.","Blood Pressure Treatment in ICU Patients with Subarachniodal Haemorrhage. -Can Blood Pressure Be Used As a Surrogate Marker for Blood Flow","BFBP","Inclusion Criteria:\n\n* Coiled or clipped aneurysm\n* Suspected or confirmed vasospasm\n\nExclusion Criteria:\n\n* BMI \\>30\n* Pregnancy\n* Pacemaker or other MRI contraindications\n* Severe congestive heart failure (NYHA III-IV) or cardiac arrhythmia.\n* Severe respiratory failure or FiO2 \\>0.6\n* Severe kidney failure",{"count":5,"type":22},[63],"An MRI study to examine the relationship between blood pressure and cerebral blood flow in patients with subarachnoidal hemorrhage and suspect or verified vasospasm.",[525,28,526],"Blood Pressure","Aneurysm Cerebral",[528,529,530],"magnetic resonance imaging","norepinephrine","blood flow","2025-03-10",{"date":533,"type":43},"2025-03-13",{"date":535,"type":43},"2023-09-01",{"date":537,"type":22},"2028-09-01",{"name":539,"class":50},"Umeå University",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":4,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":547,"enrollmentInfo":548,"targetDuration":4,"studyType":61,"phases":550,"briefSummary":551,"conditions":552,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":561,"locationsCount":51},"100290782","lumbar-drain-vs-extraventricular-drain-to-prevent-vasospasm-in-subarachnoid-hemorrhage-100290782","NCT03065231","Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage","Lumbar Drainage Compared With Extraventricular Drainage of Cerebral Spinal Fluid in Treatment of Patients With Subarachnoid Hemorrhage - a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* patients received at the UCSD Medical Center with grade II, III, IV subarachnoid hemorrhage or patients with aneurysmal SAH with radiographic evidence.\n\nExclusion Criteria:\n\n* patients under the age of 18, excluding minors from this study","110 Years",{"count":549,"type":22},100,[63],"Vasospasm is a common complication after rupture of intracranial aneurysms causing devastating neurologic deficits and death. Vasospasm has been directly associated with the amount of subarachnoid blood inside the basal cisterns. Prior literature has attempted to refine treatment of ruptured intracranial aneurysms but does not have clear guidelines on the optimal method to drain subarachnoid blood. Two methods, extraventricular drain (EVD) and lumbar drain (LD) have been compared retrospectively yet remain controversial as to which method is optimal in reducing subarachnoid blood and preventing vasospasm. This study would be a prospective randomized trial in which patients would be assigned to EVD or LD and observed to see if one method of intervention is associated with preventing clinical vasospasm, decreasing subarachnoid blood, shortening overall ICU stay, and reducing the need for a permanent ventriculoperitoneal shunt. The conclusions of this study may identify an optimal treatment modality to benefit all future patients with ruptured intracranial aneurysms.",[553,28],"Vasospasm, Intracranial","2025-02-28",{"date":556,"type":43},"2025-03-04",{"date":558,"type":43},"2017-01-01",{"date":560,"type":22},"2027-01-04",{"name":562,"class":50},"University of California, San Diego",{"id":564,"slug":565,"hasResults":12,"nctId":566,"briefTitle":567,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":571,"targetDuration":4,"studyType":61,"phases":572,"briefSummary":573,"conditions":574,"keywords":575,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":591,"completionDateStruct":592,"leadSponsor":594,"locationsCount":51},"100577095","3d-contrast-enhanced-acoustic-perfusion-imaging-in-adult-after-subarachnoid-hemorrhage-100577095","NCT06793839","3D Contrast Enhanced Acoustic Perfusion Imaging in Adult After Subarachnoid Hemorrhage","Pilot Study : Characterization of Early Brain Injury and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage by Ultrasound Localization Microscopy (ULM) 3D with an Experimental Medical Device (ESRIR)","ESRIR","Inclusion Criteria:\n\n* Admitted in neurologic ICU of the CHU Caen, Normandy, for a subarachnoid hemorrhage of the anterior circulation.\n* Usable ultrasound temporal window.\n* 18 years old and more.\n* Consent of the participant or the trusted person.\n\nExclusion Criteria:\n\n* non-aneurysmal subarachnoid haemorrhage.\n* Contraindication to ultrasound contrast agent Sonovue, including allergies to a compound.\n* Uncontrolled systemic hypertension.\n* Acute respiratory distress syndrome.\n* Pregnancy or breastfeeding mother.\n* Vulnerable person with guardianship or curatorship.\n* Patient not affiliated to french social security system (Sécurité Sociale)",{"count":479,"type":22},[63],"Aneurysmal subarachnoid hemorrhage (SAH) is a devastating form of stroke, with three major complications : early brain injury (EBI), vasospasm and delayed cerebral ischemia (DCI). Those patients are often given care in neurocritical care. Imaging is particularly useful to diagnose these complications. Brain imaging includes CT scan, MRI and arteriography which are not easily available and need an intrahospital transportation. Furthermore, intrahospital transportation of critically ill patients is associated with significant complications Here, investigators try to show that a new non-invasive bedside device, based on 3D enhanced ultrasonography, is able to detect principal arteries of anterior circulation of the brain.",[28],[576,577,33,578,579,580,154,581,582,583,584,585,586,587],"aneurysmal","subarachnoid","transcranial","doppler","ultrasonography","localizing","microscopy","delayed","cerebral","ischemia","aneurysm","anterior","2025-01-24",{"date":590,"type":43},"2025-01-27",{"date":228,"type":43},{"date":593,"type":22},"2025-03",{"name":595,"class":50},"University Hospital, Caen",{"id":597,"slug":598,"hasResults":12,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":602,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":604,"enrollmentInfo":605,"targetDuration":4,"studyType":61,"phases":607,"briefSummary":608,"conditions":609,"keywords":613,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":618,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":51},"100400125","prevention-of-vasospasm-in-sah-through-csf-treatment-100400125","NCT04490161","Prevention of Vasospasm in SAH Through CSF Treatment","Prevention of Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage Through Treatment With Intravenous Autologous Cerebrospinal Fluid - a Pilot Trial.","PREVAIL","Inclusion Criteria:\n\nAge: \\>18, \\\u003C90\n\n* SAH HH 3 - 5\n* Cerebral saccular Aneurysm\n* Digital subtraction angiography prior to aneurysm repair\n* Aneurysm repair within 72h\n* Modified Fisher Grade 3+4\n* Presence of aneurysm needing treatment (clipping or coiling)\n* Treatment within 24 hours of symptom onset\n* External ventricular drain (clinical need)\n\nExclusion Criteria:\n\n* Non-aneurysmal SAH\n\n  * SAH HH\\\u003C3\n  * Extensive intraventricular haemorrhage (unable to obtain CSF without massive aspiration of clotted blood)\n  * Contraindication for digital subtraction angiography\n  * Aneurysm repair \\>72h after rupture\n  * Signs of radiographic vasospasm upon diagnosis\n  * Presence of systemic or CSF infection\n  * Contraindication for oral Nimodipin\n  * Pregnancy","90 Years",{"count":606,"type":22},20,[63],"The pathophysiological mechanisms of aneurysmal subarachnoid haemorrhage (aSAH) involve early brain injury (EBI) and delayed cerebral ischemia (DCI).\n\nSeveral mechanisms contribute to EBI pathogenesis, including cell death, inflammatory response, oxidative stress, excitotoxicity, microcirculatory dysfunction, microthrombosis and cortical spreading depolarization. All are suggested to be linked due to common pathogenic pathways and direct interaction.\n\nDespite advances in research of diagnostics and treatment strategies, brain injury remains the major cause of death and disability in SAH patients. There is no sufficient treatment of SAH and its devastating consequences known so far. Developing and improving diagnostic methods to monitor SAH patients and to evaluate efficacy of treatment strategies are essential in SAH research. These include neuroimaging, biomarkers, and other parameters such as invasive multimodal neuromonitoring and intraoperative electrophysiological monitoring.\n\nCerebral vasospasm (CV) - mostly responsible for DCI - can be depicted on angiograms. Altogether, tremendous efforts have been taken to conquer the occurrence and sustainability of CV. The mortality of patients suffering aSAH rises up to 50% if the patients' condition is critical (Hunt\\&Hess (HH) Grade 5, WFNS Grade 5, modified Fisher Grade 4).\n\nReports of beneficial outcome in patients with pre-existing CSF shunting have been published. The hypothesis of early CSF reapplication to the bloodstream, in order to prevent CV seems to be positively approved by the mentioned reports. Nevertheless, no data could be found on the mechanisms of action in this phenomenon.\n\nTo confirm the presence of interaction of the mechanisms of EBI and evaluate the application of cerebrospinal fluid (CSF), a pilot clinical trial was planned. Due to the lack of validated animal models for aSAH it is necessary to perform the trial first-in-human. A pilot (proof of concept) trial - is done through inclusion of 10 patients with severe aSAH (≥HH4). According to clinical guidelines, these patients receive external ventricular drainages in order to drain CSF and lower intracranial pressure. An interim analysis of data will be performed after inclusion and treatment of 5 patients. Blood-\u002FCSF-sampling for further analysis will be collected before, during and after treatment according to the study protocol.",[28,610,611,612],"Subarachnoid Hemorrhage, Aneurysmal","Vasospasm, Cerebral","Aneurysmal Subarachnoid Hemorrhage",[614,615,35,248,616,617],"EVD","Aneurysm","cerebral vasospasm","cerebrospinal fluid","2024-11-25",{"date":620,"type":43},"2024-11-27",{"date":622,"type":43},"2020-01-01",{"date":624,"type":22},"2025-02-01",{"name":626,"class":50},"Medical University Innsbruck",{"id":628,"slug":629,"hasResults":12,"nctId":630,"briefTitle":631,"officialTitle":632,"acronym":633,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":18,"minAge":119,"maxAge":364,"enrollmentInfo":635,"targetDuration":4,"studyType":61,"phases":637,"briefSummary":638,"conditions":639,"keywords":646,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":51},"100498995","music-therapy-in-complex-specialist-neurorehabilitation-100498995","NCT05777499","MUSic Therapy In Complex Specialist Neurorehabilitation","Pilot Study to Evaluate MUSic Therapy in Complex Specialist Neurorehabilitation","MUSICS","Inclusion Criteria:\n\n* Age 16 years or above.\n* Clinical diagnosis of a neurological injury involving the brain, spinal cord, and\u002For peripheral nerves, sustained during the current hospital admission.\n* Participant has complex rehabilitation needs warranting admission to a specialist neurorehabilitation unit.\n* Willing and able to provide written informed consent. If the participant is unable to demonstrate sufficient mental capacity to provide informed consent, the multidisciplinary team will liaise with the participant to identify a suitable consultee to determine suitability to participate in the study in their best interests.\n\nExclusion Criteria:\n\n* Participant is medically unstable or excessively drowsy, and is unexpected to be able to tolerate an intensive rehabilitation program.\n* Participant is expected to be discharged from hospital before 10 weeks.\n* Concurrent and\u002For recent involvement in other research that is likely to interfere with the intervention within the last 3 months of study enrolment.",{"count":636,"type":22},75,[63],"Aim: Investigate whether patients undergoing specialist rehabilitation after complex neurological injury show different functional outcomes if music therapy is included in their rehabilitation program compared to usual care.\n\nBackground: Patients with complex needs following a brain, spinal cord, and\u002For peripheral nerve injury often require a period of specialist neurorehabilitation. This involves multiple therapy disciplines, led by a Consultant in Rehabilitation Medicine, Neurology, or Neuropsychiatry. Although music therapy is suggested to enhance neuroplasticity and recovery in patients with brain injury, it is not routinely commissioned in clinical care due to a lack of supportive evidence.\n\nHypothesis: Patients undergoing music therapy in addition to complex specialist rehabilitation show better functional outcomes compared to usual care.\n\nNumber of participants: 75, aged 16-80 years. Methods: Patients undergo baseline assessments and are randomised to MUSIC or CONTROL Therapy. Both arms receive 1-3 additional therapy sessions per week, matched for duration and number, total 15 hours. After approximately 10-weeks intervention, assessments are repeated. All participants then have access to music therapy until they are discharged from Neurorehabilitation Unit (NRU), with additional qualitative data collection using semi-structured interviews, field notes, staff reports, staff stress surveys, and broader ecological observations.\n\nDuration for Participants: From consent to discharge from NRU. Primary Outcome: Change in Functional Independence Measure+Functional Assessment Measure (FIM+FAM), Northwick Park Dependency Scale (NWPDS), and Barthel Activities of Daily Living pre and post 15 hours intervention.\n\nSecondary Outcome: Change in quality of life (Flourishing Scale), psychological distress (Hospital Anxiety and Depression Scale, Depression Intensity Scale Circles), social interaction (Sickness Impact Profile Social Interaction Subscale), well-being (WHO Well-Being Index), and communication (Communication Outcomes After Stroke Scale), pre and post 15 hours intervention. Mean difference in well-being (WHO Well-Being Index) throughout the intervention period between music therapy and control therapy groups. Mean difference in post-intervention pain and mood visual analogue scores between music therapy and control therapy groups.",[223,28,222,640,641,642,643,644,645],"Tumor, Brain","Autoimmune Diseases","Meningitis\u002FEncephalitis","Acquired Brain Injury","Spinal Cord Injuries","Peripheral Nervous System Diseases",[647],"Neurological injury","2024-10-21",{"date":650,"type":43},"2024-10-23",{"date":652,"type":43},"2023-06-05",{"date":654,"type":22},"2025-10",{"name":656,"class":50},"University College, London",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":663,"eligibilityCriteria":664,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":665,"targetDuration":4,"studyType":61,"phases":667,"briefSummary":669,"conditions":670,"keywords":672,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":680,"leadSponsor":682,"locationsCount":51},"100559049","phase-3-ultra-early-statin-in-patients-with-aneurysmal-subarachnoid-hemorrhage-ue-star-100559049","NCT06559072","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR)","Ultra-early STatin in Patients With Aneurysmal subaRachnoid Hemorrhage (Ue-STAR): a Randomized Controlled Trial","Ue-STAR","Inclusion Criteria:\n\n1. Male or female; Aged ≥18 years\n2. Signs and symptoms presumed aneurysmal subarachnoid hemorrhage, confirmed by radiological evidence\n3. Treatment within 6 h after symptom onset\n\nExclusion Criteria:\n\n1. Treatment with statin prior SAH\n2. Non-aSAH (e.g. traumatic subarachnoid hemorrhage, arteriovenous malformation)\n3. Treatment \\> 6 h after symptom onset\n4. Allergy to statin medications or presence of severe adverse reactions such as abnormal liver function or rhabdomyolysis\n5. Evidence of irreversible brain damage or expected death within 7 days\n6. Known severe liver or kidney disease\n7. Non-compliance with follow-up\n8. Pregnant or breastfeeding\n9. History of severe cranial or psychiatric illness\n10. Concomitant serious systemic disease\n11. Patients with malignant tumors\n12. Currently participating in another clinical trial\n13. Considered unsuitable for the clinical trial by clinical physicians or researchers",{"count":666,"type":22},522,[668],"PHASE3","A researcher-initiated and conducted multicenter, randomized controlled trial aimed at evaluating the efficacy and safety of ultra-early statin therapy in the treatment of acute aneurysmal subarachnoid hemorrhage (aSAH).",[28,610,612,671],"Hemorrhage, Aneurysmal Subarachnoid",[673,674,675],"aneurysmal subarachnoid hemorrhage","atorvastatin","Atorvastatin Calcium","2024-09-01",{"date":678,"type":43},"2024-09-05",{"date":676,"type":22},{"date":681,"type":22},"2026-09-01",{"name":683,"class":50},"The George Institute",{"id":685,"slug":686,"hasResults":12,"nctId":687,"briefTitle":688,"officialTitle":688,"acronym":4,"eligibilityCriteria":689,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":690,"targetDuration":4,"studyType":61,"phases":691,"briefSummary":692,"conditions":693,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":696,"lastUpdatePostDateStruct":697,"startDateStruct":699,"completionDateStruct":701,"leadSponsor":703,"locationsCount":4},"100526238","visar-augmented-reality-navigation-of-ventriculostomy-100526238","NCT06132139","VisAR Augmented Reality Navigation of Ventriculostomy","Inclusion Criteria:\n\n* Adult patients, 18 years and older, determined to need an external ventricular drain (EVD) or ventriculostomy catheter by the attending neurosurgeon secondary to a variety of pathologies, including obstructive hydrocephalus, trauma and subarachnoid hemorrhage.\n\nExclusion Criteria:\n\n* Patients less than 18 years of age.\n* Pregnant women.\n* Prisoners.",{"count":266,"type":22},[63],"This study is intended to evaluate the feasibility of using VisAR augmented reality surgical navigation during placement of an external ventricular drain (EVD). The investigators are interested in confirming the design of the VisAR headset is compatible with this bedside procedure.",[694,28,695],"Obstructive Hydrocephalus","Brain Trauma","2024-08-06",{"date":698,"type":43},"2024-08-07",{"date":700,"type":22},"2024-10",{"date":702,"type":22},"2025-05",{"name":704,"class":50},"Dartmouth-Hitchcock Medical Center"]